Hormonal
GLP-1 receptor agonists (specifically Liraglutide and Semaglutide) promote NASH resolution and reduce hepatic steatosis in patients with T2DM and NAFLD, primarily through weight loss and reduced de novo lipogenesis.
If lifestyle changes alone aren't enough to manage your fatty liver and diabetes, ask your doctor about GLP-1 medications like Liraglutide or Semaglutide. These drugs have been shown to significantly improve liver inflammation and fat content, with Semaglutide showing high rates of NASH resolution. They work by mimicking a gut hormone that helps regulate blood sugar and liver fat production.
liraglutide proved benefits in the resolution of NASH without any worsening of fibrosis (39%) versus placebo (9%)... 0.4 mg of semaglutide weekly was associated in 59% of cases with a resolution of NASH versus 17% in the placebo group
Why this rating
Supported by phase II/III trials (LEAN, etc.) showing statistically significant improvements in NASH resolution and steatosis.
Source
Nonalcoholic Fatty Liver Disease and Its Complex Relation with Type 2 Diabetes Mellitus—From Prevalence to Diagnostic Approach and Treatment Strategies
Cosmina-Theodora Diaconu et al. · Journal of Clinical Medicine · 2022
DOI 10.3390/jcm11175144
More from this paper
- Weight loss of 7-10% of body weight leads to significant resolution of NASH and fibrosis regression in patients with NAFLD.Good
- Pioglitazone improves NASH resolution and fibrosis stages in patients with T2DM and NAFLD, but its use is limited by side effects such as weight gain and bone fracture risk.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →